Health technology company CardieX (ASX: CDX) has reported encouraging results of a trial to validate the commercial application of its pulse wave analysis (PWA) technology in a wearable blood pressure sensor.
The company says its overarching mission is to “develop solutions for large-scale population health disorders.”
The 8-week trial included 15 people and was conducted with The Faculty of Medicine & Health Sciences at Macquarie University as part of a strategic collaboration with Blumio Inc, a US blood pressure sensor company based in Silicon Valley.
Blumio develops non-invasive radio frequency sensors designed to measure blood pressure and other cardiovascular diagnostics. The company is currently developing its sensor technology for integration with next-generation wearable devices in order to provide better health diagnostic solutions.
By collaborating together, CardieX and Blumio hope to develop a product that can effectively measure and analyse real-time medical data such as blood pressure.
The trial results published today demonstrate that combining CardieX technology together with Blumio’s sensor can accurately extract cardiovascular signals from a variety of trial patient subjects with differing cardiovascular conditions as well as being able to track changes in cardiovascular events in those patients – “thereby making the sensor suitable for specific cardiovascular monitoring applications,” according to CardieX.
As part of a multi-phase program, this first trial assessed the feasibility of obtaining cardiovascular blood pressure (BP) related data utilising Blumio’s radar frequency sensor and analysing it via CardieX PWA technology.
In order to develop and commercialise its PWA technology, CardieX is utilising its “AtCor Medical” division which develops and markets products for the early detection of target organ damage and the management of cardiovascular and renal disease.
The technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis (as measured by the company’s SphygmoCor system) provides clinicians with better prognostic and diagnostic information to determine intervention requirements.
According to CardieX, the system allows clinicians to detect effects which cannot be detected with standard brachial blood pressure measurements.
More than 4,000 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. Furthermore, CardieX technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations.
“In order to develop a commercial wearable blood pressure sensor it requires the extraction of precise cardiovascular and blood pressure data from the relevant sensor. This initial trial is extremely encouraging as a clear demonstration of the use of our technology to extract specific blood pressure data from a wearable sensor,” said Craig Cooper, CEO of CardieX.
“We are continuing to refine the data obtained in the trial but our analysis to date has shown that with further neural learning – and the application of our proprietary algorithms – we have the ability to extract a wide range of commercially viable medical and consumer data from the sensor,” said Mr Cooper.
Today’s initial trial results for CardieX’ wearable blood pressure sensor technology helped CardieX shares to reach a high of $0.042 per share by lunchtime, up around 20% on the day.